Intrinsic Therapeutics

Intrinsic Therapeutics has developed the Barricaid, a medical device designed to reduce the risk of reherniation and reoperation following lumbar discectomy surgery. The company's target market includes patients with large defects in their spinal discs who are at a higher risk of recurrent herniation. The Barricaid is intended to be a one-time, permanent implant that helps to close the hole in the spinal disc after surgery, thereby preventing the nucleus from leaking out and causing another herniation.

The business model of Intrinsic Therapeutics revolves around the sale of the Barricaid device to hospitals and surgical centers. The company has received FDA approval for the Barricaid, which is a significant milestone that allows for its commercialization in the United States. The company's revenue is generated through the sales of this device. The company has a strong focus on clinical data and has conducted studies to demonstrate the effectiveness and safety of the Barricaid.

Keywords: medical device, lumbar discectomy, reherniation, spinal surgery, implant, FDA approval, clinical data, healthcare, orthopedics, surgical device